IFNA2 and neoplasm: The former, including IFN-α and -β, has been linked to both transient and enduring immune activity against cancer cells by facilitating the priming of dendritic cells (DCs) required for T cell activation [19]; increasing tumor immunogenicity through the upregulation of major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs), which include tumor cells, to aid in specific errant cell recognition [20,21,22,23]; and, supporting immune cell migration, stimulation, and differentiation [16,24,25,26].